Latest Tech News

Stay updated with the latest in technology, AI, cybersecurity, and more

Filtered by: orforglipron Clear Filter

A Pill to Fight Obesity Is on the Verge of Approval

The next big obesity medication coming down the pipeline will likely come in pill form. Eli Lilly has just released the latest positive Phase III trial results of its experimental oral GLP-1 drug, orforglipron. On Tuesday morning, Eli Lilly reported that orforglipron met the benchmarks of the company’s Phase III ATTAIN-2 study. People taking orforglipron experienced substantial improvements in weight loss and blood sugar control compared to those taking a placebo, the study showed. Armed with d

Eli Lilly’s Obesity Pill Shows Promising Weight Loss in New Results

An experimental pill made by Eli Lilly led to average weight loss of more than 12 percent of body weight in individuals with obesity, according to initial trial results announced by the drugmaker on Thursday. The pill is meant to be taken daily and would be an alternative to the company’s popular anti-obesity drug Zepbound, a once-weekly injectable drug. Called orforglipron, it’s part of a growing class of drugs known as GLP-1s, which include Novo Nordisk’s Ozempic and Wegovy. The drugs mimic a

Eli Lilly’s Obesity Pill Appears to Work as Well as Injected GLP-1s

Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, according to new data from a Phase 3 trial. The results were announced today at the annual meeting of the American Diabetes Association and published in the New England Journal of Medicine. Eli Lilly is the maker of the blockbuster GLP-1 drug tirzepatide, approved as Mounjaro for type 2 diabetes and Zepbound